CCM
NVCR icon

Cinctive Capital Management’s NovoCure NVCR Stock Holding History

Cinctive Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,415
Closed -$827K – 448
2025
Q1 		$827K Sell
46,415
-63,397
-58% -$1.44M 0.06% 229
2024
Q4 		$3.27M Buy
+109,812
New +$2.32M 0.17% 177
2020
Q2 		– Sell
-17,465
Closed -$1.18M – 300
2020
Q1 		$1.18M Buy
+17,465
New +$1.38M 0.26% 144

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Cinctive Capital Management's NVCR Position: Q2 2025 in Review

Cinctive Capital Management sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 46,415 shares — an estimated $827K sold.

Cinctive Capital Management first reported a position in NVCR in Q1 2020 and held it in 3 quarters. The position peaked at $3.27M in Q4 2024. 242 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.

  • Cinctive Capital Management reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
  • Cinctive Capital Management sold 46,415 NovoCure shares in Q2 2025, an estimated $827K.
  • Cinctive Capital Management first reported a position in NovoCure in Q1 2020 and held it in 3 quarters.
  • Cinctive Capital Management's NovoCure position peaked at $3.27M in Q4 2024.
  • 242 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.

Based on Cinctive Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.